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Abstract: Constipation disproportionately affects older adults, with a prevalences of 50% in 
community-dwelling elderly and 74% in nursing-home residents. Loss of mobility,   medications, 
underlying diseases, impaired anorectal sensation, and ignoring calls to defecate are as   important 
as dyssynergic defecation or irritable bowel syndrome in causing constipation. Detailed medi-
cal history on medications and co-morbid problems, and meticulous digital rectal   examination 
may help identify causes of constipation. Likewise, blood tests and colonoscopy may identify 
organic causes such as colon cancer. Physiological tests such as colonic transit study with 
radio-opaque markers or wireless motility capsule, anorectal manometry, and   balloon expulsion 
tests can identify disorders of colonic and anorectal   function. However, in the elderly, there is 
usually more than one mechanism, requiring an individualized but   multifactorial treatment 
approach. The management of constipation continues to evolve. Although osmotic laxatives such 
as polyethylene glycol remain mainstay, several new agents that target different mechanisms 
appear promising such as chloride-channel activator (  lubiprostone), guanylate cyclase agonist 
(linaclotide), 5HT4 agonist (prucalopride), and peripherally acting µ-opioid receptor   antagonists 
(alvimopan and methylnaltrexone) for opioid-induced constipation. Biofeedback therapy is 
efficacious for treating dyssynergic defecation and fecal impaction with soiling. However, data 
on efficacy and safety of drugs in elderly are limited and urgently needed.
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Introduction
The management of constipation in the elderly is challenging both for patients and 
healthcare providers. Multiple reasons contribute to this phenomenon, such as the 
effects of aging on gut physiology, co-morbid illnesses, medications, loss of mobility, 
inadequate caloric intake, and anorectal sensory changes. Elderly patients, especially 
those with advanced dementia in nursing homes and those on opioids for palliative 
care, require an individualized approach for the treatment of constipation.
Definition and epidemiology
Constipation is not a well defined disease entity, but a general term used to describe 
the d  ifficulties that a subject experiences with moving their bowels.1 Healthcare 
  providers   typically define constipation as stool frequency of less than 3 bowel move-
ments per week.2 In contrast, patients define constipation as any form of “  difficult 
  defecation”, such as straining, hard stool, feeling of incomplete   evacuation, and non-
productive urge.3,4 Compared to younger patients, the elderly report more frequent 
straining,   self-digitation, and   feelings of anal blockage.4,5 In a study of 531 patients 
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in general   practice, 50% gave a different definition of 
  constipation compared to their   physicians.6 Because of these 
variable definitions of   constipation, an   international panel 
of experts proposed the Rome criteria for constipation. The 
Rome III criteria used a combination of subjective symptoms 
to define constipation,7 and are currently used widely for 
  performing clinical research in this field.
It is reported that the prevalence of constipation increases 
with age, especially those over the age of 65 years.8 In elderly 
patients living in the community, the prevalence of   constipation 
is 50%.4 This number is even higher in   nursing home residents, 
with 74% using daily laxatives.4,9–11   Likewise, elderly women 
are 2 to 3 times more likely to report constipation than their 
male counterparts.4   Constipation is also more commonly seen 
in patients taking multiple medications.12
Health-related quality of life  
and constipation
Evidence in both disease-specific and generic quality of life 
(QOL) instruments has shown that constipation is associ-
ated with impaired health-related quality of life (HR-QOL). 
For example, in one study of 126 community-dwelling older 
adults, respondents with chronic   constipation had lower 
Short-Form 36 (SF-36) scores for physical functioning, men-
tal health, general health perception, and bodily pain when 
compared to respondents with no constipation.13 Likewise, 
using the Psychological General Well-Being (PGWB) index, 
84   subjects with constipation has lower PGWB total scores 
and lower domain scores for anxiety, depression, well-being, 
self-control and general health subscales, indicating worse 
HR-QOL.14 Furthermore, improvements with HR-QOL were 
noted with treatment of constipation.15 After laxatives caused 
significant increases in weekly bowel movements, patients 
reported fewer urinary symptoms, better sexual function and 
improved mood and depression.
In addition, constipation is a significant driver of health 
care costs, as it is ranked among the top 5 most  common 
physician diagnosis for gastrointestinal   outpatient visits.4 
Using a community survey, the management of   constipation 
is estimated to average $200 per patient within a large 
HMO.16 Over $821 million dollars (2000 value) was spent on 
over-the-counter laxatives in the United States alone.8 Other 
indirect costs of constipation to society include decrease in 
work related productivity, absences in school, lower quality 
of life and higher   psychological distress.8
Normal continence and defecation
The pelvic floor consists of superficial and deep muscle 
layers that envelope the rectum, bladder and uterus.17 The 
  superficial muscle layers consist of the internal and external anal 
  sphincters, the perineal body and the transverse perinei muscles. 
In contrast, the deep pelvic muscles (also known as levator 
ani) are composed of the pubococcygeus,   ileococcygeus and 
puborectalis muscles.17 These structures are largely innervated 
by the sacral nerve roots (S2–S4) and the pudendal nerve.
Continence is the ability to retain feces until it is socially 
conducive to defecate, while defecation is the evacuation of 
fecal material from the colon. Both functions are regulated 
by voluntary and involuntary reflex mechanisms, anatomic 
factors, rectal sensation, and rectal compliance.
Defecation starts when the cerebral cortex receives an 
awareness and perception of critical level of filling in the 
rectum. When the individual adopts a sitting or squatting 
position, the anal sphincters and the puborectalis relax, 
straightening the anorectal angle. Simultaneously, the vol-
untary efforts of bearing down increases the intra-abdominal 
pressure, facilitating the development of a stripping wave, 
resulting in stool evacuation.
Common causes of constipation  
in the elderly
In the elderly, constipation most likely has a   multifactorial 
etiology, with more than one mechanism present in a single 
patient, such as co-morbid illnesses or medication side effects 
(Table 1). In the elderly, living in hospice with advanced 
cancer and pain, opioid-induced constipation is common.
Table 1 Common causes of constipation in the elderly
Medications Neurologic disorders
 •    Analgesics (opiates,  
tramadol, NSAIDs)
 •    Cerebrovascular  
disease and stroke
 •  Tricyclic antidepressants  •  Parkinson’s disease
 •  Anticholinergic agents  •  Multiple sclerosis
 •  Calcium channel blockers  •  Autonomic neuropathy
 •    Anti-parkinsonian drugs  
(dopaminergic agents)
 •  Spinal cord lesions 
  • Dementia
 •    Antipsychotics (phenothiazine derivatives)
 •    Antacids (calcium and aluminum) Myopathic disorders
 •  Calcium supplements  •  Amyloidosis
 •  Bile acid resins  •  Scleroderma
 •  Iron supplements Others
 •  Antihistamines  •  Depression
 •    Diuretics (furosemide,  
hydrochlorothiazide)
 •  General disability 
  • Poor mobility
 •  Anticonvulsants
Endocrine and metabolic diseases
 •  Diabetes mellitus
 •  Hypothyroidism
 •  Hyperparathyroidism
 •  Chronic renal diseaseClinical Interventions in Aging 2010:5 submit your manuscript | www.dovepress.com
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Furthermore, there are psychosocial and   behavioral   factors 
that may predispose the elderly to develop   constipation, such 
as decreased mobility, inadequate caloric intake, and   anorectal 
sensation changes. Ignoring calls to defecate, can lead to 
fecal retention in the elderly.4 Suppression of rectal sensation 
f  ollows chronic fecal retention. As a result, only large stools 
will be perceived, leading to difficulty with defecation.4
In the elderly, chronic constipation can lead to fecal 
impaction and fecal incontinence. Fecal impaction is the accu-
mulation of hardened feces in the colon or rectum.18 Liquid 
stools from the proximal colon can bypass the impacted stool, 
causing overflow incontinence, often   mistaken for diarrhea. 
Fecal impaction has been identified in 40% of hospitalized 
older patients in the UK.18 It has been linked to acute states 
of confusion in this population. In severe cases, fecal impac-
tion can cause stercoral ulcerations, intestinal obstruction or 
bowel perforation.18 If left untreated, these complications can 
be life threatening.
Disorders of colonic and anorectal 
function causing constipation  
in the elderly
In the absence of alarm symptoms, such as weight loss, 
bleeding, change in bowel habit, the two most commonly 
seen subtypes of primary constipation in the elderly are slow 
transit constipation (STC) and dyssynergic defecation (DD), 
with a less common subtype being irritable bowel syndrome 
with constipation (IBS-C).
Slow transit constipation
STC is defined as the delay of stool transit through the colon, 
due to a myopathy, neuropathy or secondary to an evacuation 
disorder such as DD.8
In the elderly, age related neurodegenerative changes in 
the enteric nervous system have been previously noted. There 
was a 37% loss of enteric neurons in older people (more 
than 65 years old) when compared with younger people 
(20–35 years old).4 This was associated with an increase in 
the elastic and collagen fibers in the myenteric ganglia of 
older subjects.4
Similarly, a recent study showed the selective age related 
loss of neurons expressing choline acetyltransferase with 
  sparing of neuronal nitric oxide in human colon.20 These 
  findings suggest an increase in inhibitory neurons in the aging 
colon, affecting gut motility. However, the   significance of 
these studies is unclear since these findings could   suggest 
either a primary entity or secondary to chronic use of 
laxatives and/or behavioral changes of constipated patients 
through the years.
In fact, gut transit time and colonic motility are similar 
between healthy older and younger participants.1 In contrast, 
elderly people with chronic illness reporting constipation have 
a prolonged total gut transit time of 4 to 9 days (normal is less 
than 3 days).1 In the least mobile of nursing home residents, 
transit times are prolonged up to 3 weeks.1 It appears that 
  factors related to aging, such as chronic   medical conditions and 
immobility, impact gut motility, rather than aging itself.
Dyssynergic defecation
DD is characterized by difficulty of expelling stool from the 
anorectum.8
DD is believed to be caused by failure of recto-anal 
  coordination, either by impaired rectal contraction, 
  paradoxical anal contraction, or inadequate anal relaxation.17 
Anorectal physiologic changes, such as reductions in internal 
anal sphincter pressure, pelvic muscle strength, and changes 
in rectal sensitivity have been reported in the elderly.4
Women, especially those who had sustained injuries 
during vaginal deliveries, have larger decrease in anorectal 
squeeze pressures.4 Taken together, these may predispose 
the elderly to develop DD.
Irritable bowel syndrome  
with constipation
IBS-C is largely defined by chronic or recurrent abdominal 
pain or discomfort associated with altered bowel habits, 
with $25% of stools being hard or lumpy.19 These patients 
may or may not have STC or DD. Although rare, some elderly 
subjects have IBS-C.
Diagnosis of constipation  
in the elderly
Medical history and physical examination
Constipated patients present with several symptoms. As a 
healthcare provider, it is important to ascertain the patient’s 
complaint regarding what they mean by constipation. A careful 
medical history, noting medical conditions and medications 
that affect colonic transit should be conducted (Table 1).
The history should include an assessment of stool 
  frequency, stool consistency, stool size, degree of straining 
during defecation, and a history of ignoring a call to defecate. 
A dietary history should assess the amount of fiber and water 
intake, and the number of meals and when they are consumed. 
The history should also include the number, type and frequency 
of laxatives used. In the elderly, fecal seepage and incontinence 
may be presenting symptoms of fecal impaction.
Finally, a social history with emphasis on the patient’s 
current living situation, such as living with family or alone; Clinical Interventions in Aging 2010:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
166
Rao and Go
nursing home; or in hospice are important. Furthermore, 
information about a patient’s activities of daily living, such 
as dressing and eating, and instrumental   activities of daily 
living, such as grocery shopping and housework, can provide 
clues on the patient’s functional capacity and level of cogni-
tion. Taking note of the patients’ psychiatric co-morbidities 
and psychosocial stressors are especially important in dealing 
with IBS patients.
A thorough anorectal and digital rectal exam is   essential. 
It should go beyond looking at skin erosions, skin tags, anal 
fissures, or hemorrhoids. Using a cotton bud or a blunt needle, 
gently stroke the four quadrants of the perineal skin. Neu-
ropathy is suspected if this maneuver failed to invoke a reflex 
contraction of the external anal sphincter. Finally, patients 
should be asked to bear down as if to defecate. It is important 
for the examiner to perceive relaxation of the external anal 
sphincter together with perineal descent. If these features are 
absent, one should suspect DD.
Metabolic and structural evaluation
Since constipation may be caused by an underlying 
  metabolic and pathologic disorder, routine blood tests, 
such as a   complete blood count, biochemical profile, cal-
cium levels and thyroid functions are usually performed. 
Structural tests including a flexible sigmoidoscopy or a 
colonoscopy can   provide evidence for chronic laxative use, 
such as melanosis coli, or mucosal lesions such as solitary 
rectal ulcer, inflammatory bowel disease, or malignancy. 
In the absence of a clear explanation, a functional disorder 
should be considered.
Physiological tests
In order to diagnose STC and DD, several additional 
  physiological tests are usually employed.
Colonic transit study
The colonic transit study provides a physician with a 
  better understanding of the rate of stool movement through 
the colon. The test involves the ingestion of a single 
  Stizmarks® capsule (Konsyl Pharmaceuticals, Fort Worth, 
Texas)   containing 24 radio-opaque markers on day 1 and by 
  obtaining a plain radiograph on day 6 (after 120 hours).
Normal transit is when there are less than 5 markers 
remaining in the colon.21 STC is diagnosed when 6 or more 
markers are s  cattered throughout the colon. Recently, a 
wireless motility c  apsule has been tested and found to be 
useful and safe in the elderly. This not only provides colonic 
and whole gut transit time but also provides regional transit 
time such as gastric emptying using a standardized protocol 
and is free of radiation.22
Anorectal manometry
The anorectal manometry (ARM) provides pressure   readings 
in the rectum and anal sphincters, as well as data on r  ectal 
  sensation, rectoanal reflexes, and rectal   compliance.8 In   normal 
defecation, the rectal pressure rises with a   synchronized fall 
in anal sphincter pressures. The inability to coordinate 
these anorectal processes underlies the main pathophysio-
logical abnormality in patients with DD.23 These patients 
are thought to have impaired rectal   contraction, paradoxical 
anal contraction, impaired relaxation, or a   combination of 
these mechanisms.23,24 Finally, the ARM provides informa-
tion on anorectal sensory dysfunction, as exemplified by 
higher thresholds for first sensation and thresholds for desire 
to defecate.23
Balloon expulsion test
This test is performed by inserting a silicon filled stool-like 
device called the fecom or a 4 cm long balloon filled with 
50 mL of warm water inside the patient’s rectum. Most 
  normal subjects can expel the stool-like device within 1 min-
ute. Inability to expel the device within one minute is highly 
suggestive of DD.23
Prevention and management  
of constipation in the elderly
Figure 1 shows a convenient treatment algorithm to assist the 
practitioner in devising a suitable treatment modality for a 
given patient. Specific options and treatments are discussed 
below.
Fluid intake and exercise, caloric  
intake and timed toilet training
Although useful, there is little evidence to support 
  maintenance of adequate hydration and regular non-
strenuous exercise in the management of   constipation. In a 
study involving 6 test and 9 control subjects,   consumption 
of extra fluid did not show significant   differences in stool 
output.25 Although epidemiologic   studies show sedentary 
people are 3 times more likely to report   constipation, 
studies on the effect of exercise and gut transit time are 
  inconsistent.8 In elderly patients, fluid intake should be 
monitored closely especially in those with cardiac and renal 
disease. In contrast, evidence suggests that elderly patients 
consuming fewer meals and caloric intake are more prone 
to constipation.26Clinical Interventions in Aging 2010:5 submit your manuscript | www.dovepress.com
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Patients who have a normal bowel pattern usually move 
their bowels at the same time every day, suggesting that 
defecation is partly a conditioned reflex.8 Likewise, colonic 
motor activity increases after waking and after a meal 
(  gastrocolonic reflex). These suggest that constipated patients 
may establish a regular pattern of defecation by ritualizing a 
bowel habit that takes advantage of this normal physiologic 
stimulus.8 Using the same principle, timed toiled training 
consists of educating patients to attempt a bowel movement 
at least twice a day, usually 30 minutes after meals, and to 
strain no more than 5 minutes.
Diet and fiber
Previous studies have shown that a high fiber diet increases 
stool weight and decreases colon transit time, while low fiber 
diet leads to constipation.27,28 However, patients with either 
Chronic constipation
Fecal
impaction
NO YES
Remove constipating medications
(if possible)
Increase fluid intake
Increase activity or exercise
Increase fiber intake (20–30 g/day)
Timed toilet training
Manual disimpaction
Enemas and/or suppositories
Bowel regimen to prevent recurrence
Milk of magnesia
Lactulose
Sorbitol
Senna compounds
Bisacodyl
YES NO
Effective
YES NO
Effective
Continue regimen
Continue regimen
Polyethylene glycol
(PEG)
Lubiprostone Biofeedback
therapy
(dyssynergic
defecation)
Alvimopan
methylnaltrexone
(opioid-induced
constipation)
Figure 1 Treatment algorithm for the management of chronic constipation in the elderly.Clinical Interventions in Aging 2010:5 submit your manuscript | www.dovepress.com
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STC or DD do not respond well with a dietary fiber of $30 g/
day.29 In contrast, constipated patients without an underlying 
motility disorder have improved or became symptom free 
with this amount of supplemental fiber.29 A   systematic review 
showed that bulk laxatives or fibers showed an average 
weighted increase of 1.4 (95% CI, 0.6–2.2) bowel move-
ments per week.30 A fiber intake of 20–30 g of fiber a day 
is generally recommended. A recent randomized controlled 
trial (RCT) showed that dried plums were more effective 
than psyllium in the management of mild to moderate 
constipation.31
Laxatives
Several recent reviews have discussed common classifica-
tion of laxatives, their mode of action, the recommended 
dosage, and potential side effects. In the elderly, use of 
laxatives must be individualized with special attention 
to patient’s medical history (cardiac and renal co-morbid 
conditions), drug   interactions, costs, and side effects.32 
Laxatives most commonly used in clinical practice include 
milk of magnesia, lactulose, senna compounds, bisacodyl 
and polyethylene glycol (PEG) preparations.8 In a 4-week 
study involving constipated elderly patients, 70% sorbitol 
was as efficacious as lactulose, but was cheaper and better 
tolerated.33
Similarly, a senna fiber combination (Agiolax®) in elderly 
nursing home residents improved stool   consistency, frequency 
and ease of passage, when compared with l  actulose.34 The 
senna fiber was also 40% cheaper. In a long term random-
ized, multi-center study of polyethylene glycol (PEG), 17 
grams once a day was better at achieving treatment s  uccess 
at 6 months, when compared with placebo (PEG 52% vs 
11% placebo; P , 0.001).35 Treatment success was defined 
as relief of modified Rome criteria for constipation for 50% 
or more of their treatment weeks. Furthermore, similar effi-
cacy was seen in the study’s subgroup analysis involving 75 
elderly subjects. Lastly, in a short term study of 100 patients 
with medication induced constipation, PEG at 17 g daily for 
28 days was more effective than placebo in achieving treat-
ment success (PEG 78.3% vs placebo 39.1%; P , 0.001).36 
Similar results were also observed in the subgroup of 28 
elderly patients.
Despite efforts in including the elderly in RCTs, 
most   studies on the use of laxatives in the elderly are 
limited because of small sample size and problems with 
  methodology. Side effects of laxatives such as abdominal 
discomfort, electrolyte imbalances, allergic reactions and 
hepatotoxicity have been previously reported.4
Stool softeners, suppositories  
and enemas
Although widely practiced, stool softeners have l  imited   clinical 
efficacy.4,37 Suppositories may be used in i  nstitutionalized 
patients with obstructed defecation to help with rectal 
evacuation.4
Similarly, enemas are used in this population group to 
prevent fecal impaction. Side effects such as e  lectrolyte 
imbalances have been noted with phosphate enemas 
and   rectal mucosal damage with soapsuds enema. When 
  necessary, tap water enema is the safest one to use.
Newer and upcoming treatment options
Lubiprostone
Lubiprostone is an oral bicyclic fatty acid that activates 
type 2 chloride channels on the intestinal epithelial cells, 
s  ecreting chloride and water in the gut lumen.38 In several 
  multi-center RCTs, lubiprostone, when compared to placebo, 
has consistently shown to increase complete spontaneous 
bowel movements per week, as well as improved stool con-
sistency, straining, constipation severity and   patient-reported 
treatment effectiveness.39–41 In one of the study, 10% of the 
studies participants were elderly.40
Prucalopride
Prucalopride, a dihydrobenzofurancarboxamide derivative, 
is a selective high-affinity 5HT4 receptor agonist.42 Unlike 
other drugs in its class, such as tegaserod, mosapride and 
renzapride, prucalopride has a lower affinity for the human 
Ether-a-go-go Related Gene protein (hERG).42 It is believed 
that the effects on the hERG channel may have led to the 
  unfavorable cardiovascular profile seen with tegaserod. 
Recently, in a double-blind RCT with 84 elderly nursing 
home residents with chronic constipation, 2 mg   prucalopride 
once daily for 4 weeks was safe and well tolerated.43 
  Currently, prucalopride has been released in Europe, but 
not in the USA.
Linaclotide
Linaclotide is a guanylate cyclase C receptor agonist that 
stimulates intestinal fluid secretion and transit; it also has 
been shown to reduce pain in animal models.44 In a multi-
center RCT, 310 patients with chronic constipation were 
randomly assigned to receive 75, 150, 300, or 600 µg oral 
linaclotide or placebo daily for 4 weeks.44 Compared with 
placebo, there was a significant dose related increase in 
weekly rate of spontaneous bowel movements (SBMs) in 
the linaclotide groups.Clinical Interventions in Aging 2010:5 submit your manuscript | www.dovepress.com
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Linaclotide also proved effective in improving secondary 
endpoints, such as stool consistency, straining, abdominal 
discomfort, bloating, global assessments and quality of life. 
Diarrhea was the most common adverse event.
Colchicine
Colchicine, an alkaloid substance usually used to treat gout, is 
an anti-inflammatory agent that inhibits microtubule assem-
bly in white blood cells. However, it is known to induce diar-
rhea when taken in higher doses. The mechanism of inducing 
diarrhea by colchicine is unknown. It has been reported that 
colchicine increases prostaglandin synthesis, intestinal secre-
tion and gastrointestrial motility.45 It also reduces water and 
electrolyte absorption in the intestine and increases secretion 
through a cyclic AMP mediated activity.
In a double-blind, placebo-controlled study of patients 
with STC (n = 60), colchicine was shown to be effective 
in lowering Knowles-Eccersly-Scot symptoms (KESS) 
scores.45 KESS is a valid technique in diagnosing and evalu-
ating symptoms of constipation. The mean KESS scores at 
2 months were 11.67 and 18.66 for colchicine and placebo 
groups, respectively (P = 0.0001). The authors concluded 
that low-dose colchicine (1 mg daily) is effective in the 
treatment of STC.45
Alvimopan and methylnaltrexone
Recently, alvimopan46–48 and methylnaltrexone49 have been 
introduced for the treatment of opioid-induced   constipation. 
Both agents are peripherally acting µ-opioid receptor antago-
nists that do not cross the blood–brain barrier. As a result, 
these agents have the advantage of not inhibiting the analgesic 
effects of opioids.
In a 21-day randomized trial involving 168 patients, alvimo-
pan, in a dose response manner, significantly   produced at least 
1 bowel movement in 8 hours.48 Furthermore, in a randomized, 
parallel-group, repeated dose trial   involving   methylnaltrexone, 
5 mg methylnaltrexone produced a 50%   laxation response 
within 4 hours of administration.49   Furthermore, this class of 
agents has potential uses for other narcotic induced side effects, 
such as opioid-related nausea and vomiting, urinary retention, 
pruritus or post-operative ileus.
Dyssynergic defecation and fecal impaction  
with soiling
The treatment of DD consists of fiber rich diet,   laxatives, 
timed toilet training and biofeedback therapy. The   purpose of 
biofeedback is to restore the normal pattern of d  efecation by 
using an instrument based learning process. In   biofeedback 
therapy, patients are taught diaphragmatic breathing 
  techniques to improve their abdominal push efforts and to 
synchronize this with anal relaxation. A manometric probe 
is inserted into the patient’s rectum, capturing anal and rectal 
pressure readings on a monitor. Auditory and visual feedback 
is provided to the patients as they attempt   defecation. The 
patient’s posture and breathing techniques are also   corrected. 
For sensory rectal training, a balloon in the rectum is 
d  istended with 60 mL of air to provide the patient a   sensation 
of rectal fullness or a desire to defecate.
Four RCTs that evaluated the efficacy of biofeedback 
therapy in the treatment of DD concluded that biofeedback 
is consistently superior to laxatives, standard therapy, sham 
therapy, placebo and diazepam.50–53 A preliminary study also 
showed that home biofeedback is a cost effective alternative 
when compared to office biofeedback.54
However, the efficacy of biofeedback in the elderly 
remains unclear. Since biofeedback is based on operant 
l  earning conditioning techniques, an evaluation of the 
patient’s physical and mental capabilities is important 
in assessing its usefulness in the elderly with significant 
  co-morbidities and advanced dementia.
Surgery
In patients with constipation that is refractory to medical 
therapy, surgery can be an option. Subtotal colectomy with 
ileorectal anastomosis is the treatment of choice in patients 
with refractory slow transit constipation, provided that DD 
has been excluded.55,56 Results with using segmental colonic 
resection in constipation are always disappointing.4,57
It is also important to emphasize that in patients with DD, 
surgery does not improve symptoms unless the dyssynergia 
has been corrected with biofeedback.8
Reported side effects of surgery include diarrhea, 
  incontinence and bowel obstruction.4
Furthermore, the elderly might be unfit for surgery due 
to advanced age and significant co-morbidities.
Summary
Constipation is a common polysymptomatic disorder 
a  ffecting up to 74% of elderly nursing-home residents. It 
leads to considerable economic burden, loss of work-related 
productivity, as well as decreased HR-QOL.
Multiple conditions and causes predispose the elderly 
to constipation and many factors are usually present in one 
single individual.
The past decade has given us significant mechanistic 
insights in the pathophysiology of constipation, providing Clinical Interventions in Aging 2010:5 submit your manuscript | www.dovepress.com
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us with newer therapeutic agents and modalities such as 
  lubiprostone, prucalopride, linaclotide, methylnaltrexone 
and biofeedback therapy. However, data on their efficacy, 
safety and real-life applicability in the elderly are still 
limited.
More active recruitment of the elderly in clinical trials 
is needed to provide better evidence-based management of 
constipation in this population.
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